CN104926763A - Synthetic preparation method for key intermediate of ramelteon - Google Patents
Synthetic preparation method for key intermediate of ramelteon Download PDFInfo
- Publication number
- CN104926763A CN104926763A CN201510237694.5A CN201510237694A CN104926763A CN 104926763 A CN104926763 A CN 104926763A CN 201510237694 A CN201510237694 A CN 201510237694A CN 104926763 A CN104926763 A CN 104926763A
- Authority
- CN
- China
- Prior art keywords
- formula
- dihydrobenzofuran
- reaction
- propen
- ramelteon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 title claims abstract description 45
- 229960001150 ramelteon Drugs 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 238000006243 chemical reaction Methods 0.000 claims abstract description 72
- ZZUIZMWFNOKNLN-UHFFFAOYSA-N 1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-one Chemical compound C1=C2OCCC2=C2C(=O)CCC2=C1 ZZUIZMWFNOKNLN-UHFFFAOYSA-N 0.000 claims abstract description 24
- MKWRRGVTYBMERJ-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-4-carbaldehyde Chemical compound O=CC1=CC=CC2=C1CCO2 MKWRRGVTYBMERJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000007858 starting material Substances 0.000 claims abstract description 6
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 41
- 239000000243 solution Substances 0.000 claims description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- PDZKUCSHVBYMFZ-UHFFFAOYSA-N 1-(2,3-dihydro-1-benzofuran-4-yl)prop-2-en-1-one Chemical compound C=CC(=O)C1=CC=CC2=C1CCO2 PDZKUCSHVBYMFZ-UHFFFAOYSA-N 0.000 claims description 32
- -1 1-(2,3- Dihydrobenzofuran-4-yl)-2-propen-1-ol Chemical compound 0.000 claims description 28
- 239000000706 filtrate Substances 0.000 claims description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- 239000003960 organic solvent Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000012074 organic phase Substances 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 150000004794 vinyl magnesium halides Chemical class 0.000 claims description 9
- 239000002841 Lewis acid Substances 0.000 claims description 8
- 150000007517 lewis acids Chemical class 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 8
- 239000005457 ice water Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002808 molecular sieve Substances 0.000 claims description 6
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 claims description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- HZXJVDYQRYYYOR-UHFFFAOYSA-K scandium(iii) trifluoromethanesulfonate Chemical compound [Sc+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HZXJVDYQRYYYOR-UHFFFAOYSA-K 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 3
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 3
- 229910021536 Zeolite Inorganic materials 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims description 3
- 229940117975 chromium trioxide Drugs 0.000 claims description 3
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 claims description 3
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 claims description 3
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 claims description 3
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 3
- 239000010457 zeolite Substances 0.000 claims description 3
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 claims description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 2
- UCYRAEIHXSVXPV-UHFFFAOYSA-K bis(trifluoromethylsulfonyloxy)indiganyl trifluoromethanesulfonate Chemical compound [In+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F UCYRAEIHXSVXPV-UHFFFAOYSA-K 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- BSUSEPIPTZNHMN-UHFFFAOYSA-L cobalt(2+);diperchlorate Chemical compound [Co+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O BSUSEPIPTZNHMN-UHFFFAOYSA-L 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- YRNNKGFMTBWUGL-UHFFFAOYSA-L copper(ii) perchlorate Chemical compound [Cu+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O YRNNKGFMTBWUGL-UHFFFAOYSA-L 0.000 claims description 2
- 229940117389 dichlorobenzene Drugs 0.000 claims description 2
- CKFMJXZQTNRXGX-UHFFFAOYSA-L iron(2+);diperchlorate Chemical compound [Fe+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O CKFMJXZQTNRXGX-UHFFFAOYSA-L 0.000 claims description 2
- LHOWRPZTCLUDOI-UHFFFAOYSA-K iron(3+);triperchlorate Chemical compound [Fe+3].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O LHOWRPZTCLUDOI-UHFFFAOYSA-K 0.000 claims description 2
- IJMWREDHKRHWQI-UHFFFAOYSA-M magnesium;ethene;chloride Chemical compound [Mg+2].[Cl-].[CH-]=C IJMWREDHKRHWQI-UHFFFAOYSA-M 0.000 claims description 2
- 239000012452 mother liquor Substances 0.000 claims description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 claims description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 2
- 235000011150 stannous chloride Nutrition 0.000 claims description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 claims description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 2
- CSIFGMFVGDBOQC-UHFFFAOYSA-N 3-iminobutanenitrile Chemical compound CC(=N)CC#N CSIFGMFVGDBOQC-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- UMLGSQORQWPTRW-UHFFFAOYSA-N [O-2].[O-2].[O-2].[Cr+3].[Cr+3].C1=CC=NC=C1.C1=CC=NC=C1 Chemical compound [O-2].[O-2].[O-2].[Cr+3].[Cr+3].C1=CC=NC=C1.C1=CC=NC=C1 UMLGSQORQWPTRW-UHFFFAOYSA-N 0.000 claims 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 claims 1
- 238000010025 steaming Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- 238000006229 Nazarov cyclization reaction Methods 0.000 abstract description 7
- 238000003747 Grignard reaction Methods 0.000 abstract description 4
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 4
- 238000007086 side reaction Methods 0.000 abstract description 4
- 238000001308 synthesis method Methods 0.000 abstract description 3
- 238000011112 process operation Methods 0.000 abstract description 2
- 238000007363 ring formation reaction Methods 0.000 abstract description 2
- 239000004098 Tetracycline Substances 0.000 abstract 1
- 229960002180 tetracycline Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 12
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 0 C[C@@](CC(CC1)C2=CC1OC)C2=* Chemical compound C[C@@](CC(CC1)C2=CC1OC)C2=* 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 3
- 238000005893 bromination reaction Methods 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 150000003333 secondary alcohols Chemical class 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- YKUNZXPPPOCKHZ-UHFFFAOYSA-N C=CC(c1c(CCO2)c2ccc1)O Chemical compound C=CC(c1c(CCO2)c2ccc1)O YKUNZXPPPOCKHZ-UHFFFAOYSA-N 0.000 description 2
- ABMDIECEEGFXNC-UHFFFAOYSA-N CCC(NCC)=O Chemical compound CCC(NCC)=O ABMDIECEEGFXNC-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical class Br* 0.000 description 2
- TWLCEYWYILDCDA-UHFFFAOYSA-N chromium(6+) oxygen(2-) pyridine Chemical compound [O-2].[O-2].[O-2].[Cr+6].C1=CC=NC=C1.C1=CC=NC=C1 TWLCEYWYILDCDA-UHFFFAOYSA-N 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000003328 mesylation reaction Methods 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- UJGDLLGKMWVCPT-UHFFFAOYSA-N 6-methoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC=C2CCC(=O)C2=C1 UJGDLLGKMWVCPT-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- BURWKXUNJOXCGV-UHFFFAOYSA-N CCC(NCCC1c2cc(OC)ccc2CC1)=O Chemical compound CCC(NCCC1c2cc(OC)ccc2CC1)=O BURWKXUNJOXCGV-UHFFFAOYSA-N 0.000 description 1
- WPYHPSSKJGHTRD-UHFFFAOYSA-N C[O]1C2=CCC(CCC3)C3C2CC1 Chemical compound C[O]1C2=CCC(CCC3)C3C2CC1 WPYHPSSKJGHTRD-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 239000012027 Collins reagent Substances 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 229940121723 Melatonin receptor agonist Drugs 0.000 description 1
- 102100024930 Melatonin receptor type 1A Human genes 0.000 description 1
- 101710098568 Melatonin receptor type 1A Proteins 0.000 description 1
- 102100024970 Melatonin receptor type 1B Human genes 0.000 description 1
- 101710098567 Melatonin receptor type 1B Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-M barbiturate Chemical compound O=C1CC(=O)[N-]C(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-M 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 125000000950 dibromo group Chemical group Br* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- BTZNPZMHENLISZ-UHFFFAOYSA-M fluoromethanesulfonate Chemical compound [O-]S(=O)(=O)CF BTZNPZMHENLISZ-UHFFFAOYSA-M 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 150000002471 indium Chemical class 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007149 pericyclic reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940071773 rozerem Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
本发明公开了雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的合成制备方法。该制备方法以2,3-二氢苯并呋喃-4-甲醛为起始原料,经过格式反应、氧化反应和Nazarov环合反应合成雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮。该制备方法具有反应选择性高、副反应少、总收率和产品质量高、对环境友好、工艺操作简便且稳定性和可控性高等优点,适合于工业化大生产。The invention discloses a synthesis and preparation method of ramelteon key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one. The preparation method uses 2,3-dihydrobenzofuran-4-carboxaldehyde as the starting material, and synthesizes the key intermediate 1,2,6,7-tetracycline of ramelteon through Grignard reaction, oxidation reaction and Nazarov ring closure reaction. Hydrogen-8H-indeno[5,4-b]furan-8-one. The preparation method has the advantages of high reaction selectivity, less side reactions, high total yield and product quality, environmental friendliness, simple process operation, high stability and controllability, and is suitable for large-scale industrial production.
Description
技术领域technical field
本发明涉及一种雷美替胺关键中间体的合成制备方法,属于药物合成领域。The invention relates to a method for synthesizing and preparing a key intermediate of ramelteon, belonging to the field of drug synthesis.
背景技术Background technique
当前,国内外临床用于治疗失眠症的药物主要包括:巴比妥类药物、苯二氮受体激动剂、非苯二氮受体激动剂及具有镇静催眠作用的天然药物。长期使用巴比妥类镇静催眠药,患者容易产生药物耐受性、依赖性、戒断症状严重、治疗指数低等问题,甚至可致严重肝肾毒性,所以该类药物不适宜长期使用。苯二氮受体激动剂和非苯二氮类催眠药可以缩短入睡潜伏期,提高失眠患者的睡眠效率,长期或高剂量服用并不有助于失眠患者的睡眠改善,会产生戒断现象、反跳性失眠、耐受、依赖等副作用。具有镇静催眠作用的天然药物无论是单方还是复方都有较高的抗失眠作用,但是受到药材的限制,中药炮制程序的复杂,所以难以在人群中进行推广。因此,研发出一种口服的、能有效的治疗失眠、无成瘾性、适用人群广的安眠药成为急切的临床需求。At present, the drugs used clinically at home and abroad to treat insomnia mainly include: barbiturates, benzodiazepines Agonists, nonbenzodiazepines Receptor agonists and natural medicines with sedative and hypnotic effects. Long-term use of barbiturate sedative-hypnotics may lead to drug tolerance, dependence, severe withdrawal symptoms, low therapeutic index, and even severe liver and kidney toxicity. Therefore, such drugs are not suitable for long-term use. Benzodiazepines Agonists and nonbenzodiazepines Hypnotics can shorten the sleep latency and improve the sleep efficiency of patients with insomnia. Long-term or high-dose use does not help patients with insomnia to improve their sleep, but will cause side effects such as withdrawal, rebound insomnia, tolerance, and dependence. Natural medicines with sedative and hypnotic effects have high anti-insomnia effects whether they are unilateral or compound. However, due to the limitation of medicinal materials and the complicated processing procedures of traditional Chinese medicine, it is difficult to promote them among the crowd. Therefore, it has become an urgent clinical need to develop an oral, effective treatment of insomnia, non-addictive, and widely applicable sleeping pills.
雷美替胺(Ramelteon)临床用于治疗难以入睡型失眠症,它是由日本武田公司研发,商品名为Rozerem。雷美替胺是FDA批准的首个褪黑激素受体激动剂,可选择性的诱导MT1和MT2受体,对MT3没有亲和能力。它能调节体内的睡眠周期,而不影响体内中枢神经系统,对GABA受体、多巴胺受体、乙酰胆碱受体、去甲肾上腺素受体、阿片受体没有亲合性。临床研究显示雷美替胺能有效缩短患者入睡的时间,增加总的睡眠时间,并且对第二天工作、学习的影响较小,停药后的复发率也很低,临床研究中均未见药物成瘾,无明显不良反应。未来在失眠症的治疗方面,雷美替胺将发挥越来越大的作用。雷美替胺的化学名称为:(S)-N-[2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙基]丙酰胺,CAS号为:196597-26-9,其化学结构式如下所示:Ramelteon (Ramelteon) is clinically used to treat insomnia with difficulty falling asleep. It is developed by Takeda Corporation of Japan, and its trade name is Rozerem. Ramelteon is the first melatonin receptor agonist approved by the FDA, which can selectively induce MT1 and MT2 receptors, but has no affinity for MT3. It can regulate the sleep cycle in the body without affecting the central nervous system in the body, and has no affinity for GABA receptors, dopamine receptors, acetylcholine receptors, norepinephrine receptors, and opioid receptors. Clinical studies have shown that ramelteon can effectively shorten the time for patients to fall asleep, increase the total sleep time, and have less impact on the next day's work and study, and the recurrence rate after drug withdrawal is also very low, which has not been seen in clinical studies Drug addiction, no obvious adverse reactions. In the future, ramelteon will play an increasingly important role in the treatment of insomnia. The chemical name of ramelteon is: (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl] Propionamide, CAS number: 196597-26-9, its chemical structure is as follows:
雷美替胺的合成方法已见诸多报道。最早的文献(Journal of Medicinal Chemistry,2002,45,4222~4239.)报道的雷美替胺的合成方法比较复杂,合成路线很长,多步反应的化学选择性不高,总收率低,不适合工业化生产。合成路线如下所示:The synthetic method of ramelteon has been seen in many reports. The earliest literature (Journal of Medicinal Chemistry, 2002, 45, 4222~4239.) reported that the synthetic method of ramelteon is more complicated, the synthetic route is very long, the chemoselectivity of the multi-step reaction is not high, and the total yield is low. Not suitable for industrial production. The synthetic route is as follows:
蒋龙等(中国医药工业杂志,2009,40,161-164.)报道了以2,3-二氢苯并呋喃为起始原料,经过11步反应得到雷美替胺。该方法在构建雷美替胺的关键中间体(即1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮)时,采用了在苯环上先用二溴代占位,在付克酰基化之后,再用催化加氢的方法脱去两个溴。该方法存在以下的问题:(1)由于溴原子是强吸电子基团,苯环上同时在两个位置进行溴代的难度比较大,第二个位置的溴代反应很难完全。同样,在催化加氢脱去两个溴的反应中,反应也很难完全。因此,采用二溴代占位的方法必然给中间体和最终产品带来较多的杂质,影响产品的质量。(2)溴代反应,必然产生大量的酸性废水,给工业化大规模生产带来很大的环保压力。(3)类似于保护和脱保护,二溴代占位的方法延长了工艺路线,必然使得总收率下降,生产成本增加。合成路线如下所示:Jiang Long et al. (Chinese Journal of Pharmaceutical Industry, 2009, 40, 161-164.) reported that ramelteon was obtained through 11 steps of reaction using 2,3-dihydrobenzofuran as the starting material. In this method, when constructing the key intermediate of ramelteon (i.e. 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one), a First use dibromo to take up the position, and then use catalytic hydrogenation method to remove two bromines after Fuke acylation. This method has the following problems: (1) Since the bromine atom is a strong electron-withdrawing group, it is relatively difficult to carry out bromination at two positions on the benzene ring, and the bromination reaction at the second position is difficult to complete. Similarly, in the reaction of catalytic hydrogenation to remove two bromines, the reaction is difficult to complete. Therefore, adopting the method for dibromo-occupying must bring more impurities to intermediates and final products, which affects the quality of products. (2) The bromination reaction will inevitably produce a large amount of acid waste water, which will bring great environmental protection pressure to industrialized large-scale production. (3) Similar to protection and deprotection, the method of dibromo-occupying prolongs the process route, which inevitably reduces the total yield and increases the production cost. The synthetic route is as follows:
中国专利(CN20081004587.5)报道了在上面路线的基础上,采用(R)-α-苯乙胺作为拆分剂的改进方法。合成路线如下所示:Chinese patent (CN20081004587.5) reports an improved method using (R)-α-phenylethylamine as a resolving agent on the basis of the above route. The synthetic route is as follows:
PCT专利(WO2006030739)报道了采用不对称催化氢化的方法来构建手性中心。该方法所采用的手性配体价格较昂贵,催化氢化需要高压条件。合成路线如下所示:PCT patent (WO2006030739) reported the use of asymmetric catalytic hydrogenation to construct chiral centers. The chiral ligands used in this method are relatively expensive, and catalytic hydrogenation requires high pressure conditions. The synthetic route is as follows:
还有文献(Organic Preparations and Procedures International,2009,41,309-314.)报道了以6-甲氧基茚酮为起始原料合成雷美替胺的关键中间体(即1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮)的方法,经过6步反应得到目标产品。该工艺路线采用的起始原料6-甲氧基茚酮,市场价格较贵。σ重排需要在超高温条件下完成,且存在区域选择性的问题。在甲磺酰化反应中,甲磺酰氯对酚羟基和脂肪伯羟基也存在选择性的问题,如果甲磺酰化发生在酚羟基上,随后的闭环反应将不易反应完全。合成路线如下所示:There are also documents (Organic Preparations and Procedures International, 2009, 41, 309-314.) reported that the key intermediate of ramelteon (i.e. 1,2,6,7- Tetrahydro-8H-indeno[5,4-b]furan-8-one) method, through 6 steps of reaction to obtain the target product. The starting raw material 6-methoxyindanone that this operational route adopts has a more expensive market price. The σ rearrangement needs to be completed under ultra-high temperature conditions, and there is a problem of regioselectivity. In the mesylation reaction, methanesulfonyl chloride also has a selectivity problem for phenolic hydroxyl and aliphatic primary hydroxyl. If mesylation occurs on the phenolic hydroxyl, the subsequent ring closure reaction will not be easy to react completely. The synthetic route is as follows:
发明内容Contents of the invention
本发明的目的在于提供一种合成雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的合成制备方法,旨在克服以上雷美替胺合成方法中存在的副反应和杂质较多、环境污染大、起始原料不易得、生产成本较高等一些不足之处。The object of the present invention is to provide a synthetic preparation method for the key intermediate of ramelteon 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one, aiming at Overcome some shortcomings such as side reactions and impurities in the above synthetic method of ramelteon, large environmental pollution, difficult acquisition of starting materials, and higher production costs.
本发明提供一种雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的合成制备方法,其化学结构式如下式I所示:The present invention provides a method for the synthesis and preparation of ramelteon key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one, whose chemical structural formula is as follows: Formula I Shown:
本发明所提供的式I所示的合成雷美替胺的关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮,其合成制备方法如下:The key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one, the key intermediate for the synthesis of ramelteon represented by formula I provided by the present invention, is synthesized and prepared Methods as below:
(1)以式II所示的2,3-二氢苯并呋喃-4-甲醛为起始原料,与乙烯基卤化镁在一定条件下反应得到式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇;(1) With 2,3-dihydrobenzofuran-4-carbaldehyde shown in formula II as the starting material, react with vinylmagnesium halide under certain conditions to obtain 1-(2,3- Dihydrobenzofuran-4-yl)-2-propen-1-ol;
(2)式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇在氧化条件下反应得到式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮;(2) 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ol shown in formula III reacts under oxidation conditions to obtain 1-(2,3 shown in formula IV -Dihydrobenzofuran-4-yl)-2-propen-1-one;
(3)式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮在酸性条件下反应得到式I所示的雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮。(3) 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one shown in formula IV reacts under acidic conditions to obtain ramelteon key intermediate shown in formula I Body 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one.
以上所述的式II、式III和式IV所示的化合物的化学结构及式I所示的雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的合成路线如下所示:The chemical structure of the compound shown in the above formula II, formula III and formula IV and the key intermediate of ramelteon shown in formula I 1,2,6,7-tetrahydro-8H-indeno[5, 4-b] The synthetic route of furan-8-one is as follows:
在上述的雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的合成路线中,由式II所示的2,3-二氢苯并呋喃-4-甲醛与乙烯基卤化镁反应来制备式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇的反应是经典的格式反应(Grignard Reaction)。格氏反应是有机合成中应用最为广泛的反应之一,在羰基化合物的C-烃化反应中占有很重要的地位。格式反应一般常用醚类作为反应溶剂,比如四氢呋喃、乙醚、乙二醇二甲醚、异丙醚、叔丁醚、1,4-二氧六环等,也可以在惰性的芳香族溶剂中进行。In the synthetic route of the above-mentioned ramelteon key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one, 2, 3-Dihydrobenzofuran-4-carbaldehyde reacts with vinylmagnesium halide to prepare 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ol shown in formula III The reaction is a classic format reaction (Grignard Reaction). The Grignard reaction is one of the most widely used reactions in organic synthesis, and plays an important role in the C-alkylation of carbonyl compounds. Grignard reactions generally use ethers as reaction solvents, such as tetrahydrofuran, diethyl ether, ethylene glycol dimethyl ether, isopropyl ether, tert-butyl ether, 1,4-dioxane, etc., and can also be carried out in inert aromatic solvents .
由式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇氧化得到式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮的反应是常见的仲醇氧化为酮的反应。很多氧化剂可以很容易将仲醇氧化成酮(March高等有机化学-反应、机理与结构,Michael B.Smith,Jerry March编著,李艳梅译,化学工业出版社,2011年,p720~722.)。其中包括六价的铬试剂,如三氧化铬二吡啶(Collins试剂)、铬酸和硫酸溶液(Jones试剂)、氯铬酸吡啶鎓盐(PCC试剂)等;和金属锰类的氧化剂,如二氧化锰、高锰酸钾等。1-(2,3-dihydrobenzofuran-4-yl)-2-propene-1-alcohol is oxidized to obtain 1-(2,3-dihydrobenzofuran shown in formula IV by formula III The reaction of -4-yl)-2-propen-1-one is a common oxidation reaction of secondary alcohols to ketones. Many oxidants can easily oxidize secondary alcohols to ketones (March Advanced Organic Chemistry - Reaction, Mechanism and Structure, edited by Michael B. Smith, Jerry March, translated by Li Yanmei, Chemical Industry Press, 2011, p720~722.). Including hexavalent chromium reagents, such as chromium trioxide bipyridine (Collins reagent), chromic acid and sulfuric acid solution (Jones reagent), pyridinium chlorochromate (PCC reagent), etc.; Manganese oxide, potassium permanganate, etc.
此外,高价碘试剂作为氧化剂,因具有反应条件温和、产率高、选择性好、对环境友好等特点,在仲醇氧化到酮的反应中得到非常广泛的应用(有机化学,2006,26,1623~1630.)。高价碘试剂常用的有2-碘酰基苯甲酸(2-Iodoxybenzoic acid,IBX)和(1,1,1-三乙酰氧基)-1,1-二氢-1,2-苯碘酰-3(1H)-酮(Dess-Martin试剂,DMP)。In addition, as an oxidizing agent, hypervalent iodine reagent has been widely used in the oxidation of secondary alcohols to ketones due to its mild reaction conditions, high yield, good selectivity, and environmental friendliness (Organic Chemistry, 2006, 26, 1623~1630.). Hypervalent iodine reagents commonly used are 2-iodoxybenzoic acid (IBX) and (1,1,1-triacetoxy)-1,1-dihydro-1,2-phenyliodyl-3 (1H)-Kone (Dess-Martin reagent, DMP).
由式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮在酸性条件下反应得到式I所示的雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的反应是经典的Nazarov环化反应,本质上是一种周环反应。对Nazarov环化反应的研究已经非常深入了,这也是一类非常成熟、应用很广泛的反应(Organic Reactions,1994,45,1~158.;Tetrahedron,2005,61,7577-7606.)。Nazarov反应需要在酸性条件下进行,使用最经典是质子酸,如浓硫酸、多聚磷酸、磷酸、高氯酸等,较新的研究发现三氟乙酸、三氟甲磺酸等质子酸对Nazarov反应也非常有效。除了质子酸条件,现在研究更多的是采用Lewis酸的条件,包括传统的三氯化铝、四氯化锡、三氯化铁、三氟化硼乙醚络合物等,而最新的研究显示新型的三氟甲磺酸的铜盐、铁盐、铟盐等和金属钯类的Lewis酸对Nazarov反应具有更高的活性,可以在催化量下完成该反应,且反应收率很高(Tetrahedron,2005,61,7577-7606.)。此外,对环境友好的固体酸,如沸石分子筛或改性的沸石分子筛,也可以很好地催化Nazarov反应(Applied Catalysis A:General,2008,336,101~108.)。1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ketone shown in formula IV reacts under acidic conditions to obtain ramelteon key intermediate 1 shown in formula I , The reaction of 2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one is a classic Nazarov cyclization reaction, which is essentially a pericyclic reaction. The research on the Nazarov cyclization reaction has been very in-depth, which is also a very mature and widely used reaction (Organic Reactions, 1994, 45, 1-158.; Tetrahedron, 2005, 61, 7577-7606.). The Nazarov reaction needs to be carried out under acidic conditions, and the most classic ones are protonic acids, such as concentrated sulfuric acid, polyphosphoric acid, phosphoric acid, perchloric acid, etc. Newer studies have found that protonic acids such as trifluoroacetic acid and trifluoromethanesulfonic acid have a negative effect on Nazarov reaction. Response is also very effective. In addition to protonic acid conditions, more studies are now using Lewis acid conditions, including traditional aluminum trichloride, tin tetrachloride, ferric chloride, boron trifluoride ether complex, etc., and the latest research shows Novel copper salts of trifluoromethanesulfonic acid, iron salts, indium salts, etc. and the Lewis acid of metal palladium have higher activity to the Nazarov reaction, and the reaction can be completed in a catalytic amount, and the reaction yield is very high (Tetrahedron , 2005, 61, 7577-7606.). In addition, environmentally friendly solid acids, such as zeolite molecular sieves or modified zeolite molecular sieves, can also catalyze the Nazarov reaction well (Applied Catalysis A: General, 2008, 336, 101-108.).
具体的,本发明所提供的式I所示的雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的合成制备方法可以按照如下步骤实现:Specifically, the synthesis and preparation of the key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one of ramelteon shown in formula I provided by the present invention The method can be implemented as follows:
步骤1:在反应瓶中加入乙烯基卤化镁的四氢呋喃溶液,在一定的温度A条件下滴加一定量的式II所示的2,3-二氢苯并呋喃-4-甲醛溶于有机溶剂A的溶液,反应一定时间A后,升至室温,再反应一定的时间B后,加入饱和氯化铵溶液,搅拌,乙酸乙酯萃取,洗涤,干燥,过滤,滤液减压蒸除溶剂后,即得到式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇。Step 1: Add a tetrahydrofuran solution of vinylmagnesium halide in the reaction flask, add dropwise a certain amount of 2,3-dihydrobenzofuran-4-carbaldehyde represented by formula II in an organic solvent at a certain temperature A The solution of A, after reacting for a certain period of time A, rises to room temperature, and after reacting for a certain period of time B, add saturated ammonium chloride solution, stir, extract with ethyl acetate, wash, dry, filter, and after the filtrate is evaporated under reduced pressure to remove the solvent, That is, 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ol represented by formula III is obtained.
步骤1中所述的有机溶剂A可选择四氢呋喃、乙醚、乙二醇二甲醚、异丙醚、叔丁醚、1,4-二氧六环、苯、甲苯、二甲苯中的一种或多种混合溶剂。The organic solvent A described in step 1 can be selected from one of tetrahydrofuran, diethyl ether, ethylene glycol dimethyl ether, isopropyl ether, tert-butyl ether, 1,4-dioxane, benzene, toluene, xylene or Various mixed solvents.
步骤1中所述的乙烯基卤化镁可选择乙烯基溴化镁或乙烯基氯化镁。The vinylmagnesium halide described in step 1 can be selected from vinylmagnesium bromide or vinylmagnesium chloride.
步骤1中所述的反应温度A的范围为-80~0℃。The reaction temperature A described in step 1 ranges from -80 to 0°C.
步骤1中所述的反应时间A的范围为0.1~1小时,反应时间B的范围为1~10小时。The range of reaction time A described in step 1 is 0.1-1 hour, and the range of reaction time B is 1-10 hours.
步骤1中所述的式II所示的化合物和乙烯基卤化镁的投料摩尔比为1:0.5~1.5。The molar ratio of the compound represented by formula II and vinylmagnesium halide in step 1 is 1:0.5-1.5.
步骤2可以采用以下三种方法来实现。Step 2 can be implemented in the following three ways.
步骤2的方法一:在有机溶剂B中,室温下,加入一定量的式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇和一定量的2-碘酰基苯甲酸,再在室温下或升温至反应温度B进行反应,TLC检测反应,直至原料点消失,反应液降温到室温后,加入乙酸乙酯稀释,过滤,母液再用水洗涤,干燥,过滤,滤液减压蒸除溶剂后,即得到式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮。Method 1 of step 2: In organic solvent B, at room temperature, add a certain amount of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ol and a certain amount of formula III A certain amount of 2-iodylbenzoic acid is reacted at room temperature or heated up to reaction temperature B, and the reaction is detected by TLC until the raw material point disappears. After the reaction solution is cooled to room temperature, ethyl acetate is added for dilution, filtered, and the mother liquor is washed with water. , dried, filtered, and the filtrate was evaporated to remove the solvent under reduced pressure to obtain 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one represented by formula IV.
步骤2的方法一中所述的有机溶剂B可选择二甲亚砜、四氢呋喃、乙腈、丙酮、乙酸乙酯、1,2-二氯乙烷中的一种或多种混合溶剂。The organic solvent B described in method 1 of step 2 can be selected from one or more mixed solvents of dimethyl sulfoxide, tetrahydrofuran, acetonitrile, acetone, ethyl acetate, and 1,2-dichloroethane.
步骤2的方法一中所述的反应温度B的范围为40~80℃。The range of reaction temperature B described in method one of step 2 is 40-80°C.
步骤2的方法一中所述的式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇和2-碘酰基苯甲酸的投料摩尔比为1:1.1~3.0。The molar ratio of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-alcohol and 2-iodylbenzoic acid shown in the formula III described in the method one of step 2 is 1: 1.1 ~ 3.0.
步骤2的方法二:在有机溶剂C中,室温下,加入一定量的式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇,搅拌溶解后再加入一定量的(1,1,1-三乙酰氧基)-1,1-二氢-1,2-苯碘酰-3(1H)-酮,继续在室温下反应,TLC检测,直至原料点消失,加入乙酸乙酯、10%的Na2S2O3溶液和饱和NaHCO3溶液,剧烈搅拌1小时后,分出有机相,洗涤,干燥,过滤,滤液减压蒸除溶剂后,即得到式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮。Method 2 of step 2: in an organic solvent C, at room temperature, add a certain amount of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ol represented by formula III, Stir to dissolve, then add a certain amount of (1,1,1-triacetoxy)-1,1-dihydro-1,2-phenyliodyl-3(1H)-one, continue to react at room temperature, TLC Detect until the raw material point disappears, add ethyl acetate, 10% Na 2 S 2 O 3 solution and saturated NaHCO 3 solution, stir vigorously for 1 hour, separate the organic phase, wash, dry, filter, and evaporate the filtrate under reduced pressure After solvent, 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one represented by formula IV is obtained.
步骤2的方法二中所述的有机溶剂C可选择二氯甲烷、氯仿、乙腈、四氢呋喃中的一种或多种混合溶剂。The organic solvent C described in method 2 of step 2 can be selected from one or more mixed solvents of dichloromethane, chloroform, acetonitrile, and tetrahydrofuran.
步骤2的方法二中所述的式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇和(1,1,1-三乙酰氧基)-1,1-二氢-1,2-苯碘酰-3(1H)-酮的投料摩尔比为1:1.1~3.0。1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-alcohol and (1,1,1-triacetoxy )-1,1-dihydro-1,2-phenyliodyl-3(1H)-one molar ratio is 1:1.1~3.0.
步骤2的方法三:室温下,将溶解有一定量的式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇的二氯甲烷溶液,加入到新鲜制备的三氧化铬二吡啶的二氯甲烷溶液中,继续在室温下搅拌反应,TLC检测,直至原料点消失,过滤,滤液经洗涤后,干燥,再过滤,滤液减压蒸除溶剂后,即得到式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮。Method 3 of step 2: at room temperature, a dichloromethane solution in which a certain amount of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ol represented by formula III is dissolved, Add to the dichloromethane solution of freshly prepared chromium trioxide dipyridine, continue to stir the reaction at room temperature, TLC detection, until the raw material point disappears, filter, the filtrate is washed, dried, and then filtered, the filtrate is decompressed to remove the solvent After that, 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one represented by formula IV is obtained.
步骤2的方法三中所述的式III所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇和三氧化铬二吡啶的投料摩尔比为1:5.0~7.0。The molar ratio of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-alcohol and chromium trioxide dipyridine shown in the formula III described in step 2 is 1 : 5.0~7.0.
步骤3可以采用以下二种方法来实现。Step 3 can be realized by the following two methods.
步骤3的方法一:室温下,向一定量的质子酸中加入一定量的式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮,继续在室温或加热到温度C进行反应,TLC检测反应,直至原料点消失,将反应液缓慢加入到冰水混合物中淬灭反应,再用二氯甲烷萃取多次,有机相经洗涤后,干燥,过滤,滤液减压蒸除溶剂后,用乙醇重结晶,即得到式I所示的雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮。Method 1 of step 3: at room temperature, add a certain amount of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one shown in formula IV to a certain amount of protonic acid , continue to react at room temperature or heated to temperature C, TLC detection reaction, until the raw material point disappears, the reaction solution is slowly added to the ice-water mixture to quench the reaction, and then extracted with dichloromethane for several times, after the organic phase is washed, After drying and filtering, the filtrate was evaporated to remove the solvent under reduced pressure, and recrystallized with ethanol to obtain the key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4 -b] furan-8-one.
步骤3的方法一中所述的质子酸可选择浓硫酸、磷酸、多聚磷酸、高氯酸、三氟乙酸、三氟甲磺酸中的一种或多种混合酸。The protonic acid described in method one of step 3 can be selected from one or more mixed acids of concentrated sulfuric acid, phosphoric acid, polyphosphoric acid, perchloric acid, trifluoroacetic acid, and trifluoromethanesulfonic acid.
步骤3的方法一中所述的反应温度C的范围为40~120℃。The range of reaction temperature C described in method one of step 3 is 40-120°C.
步骤3的方法一中所述的式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮和质子酸的投料重量比为1:2.0~7.0。The weight ratio of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one and protonic acid represented by formula IV described in method 1 of step 3 is 1:2.0 ~7.0.
步骤3的方法二:在有机溶剂D中,加入一定量的式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮,搅拌溶解,控制反应液的温度在温度D下,加入Lewis酸。控制反应液的温度在温度E下继续反应,TLC检测反应,直至原料点消失,冷却后将反应液缓慢加入到冰水混合物中淬灭反应,分出有机相,再用二氯甲烷萃取水相多次,合并有机相,经洗涤后干燥,过滤,滤液减压蒸除溶剂后,用乙醇重结晶,即得到式I所示的雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮。Method 2 of step 3: In the organic solvent D, add a certain amount of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one represented by formula IV, stir and dissolve, Control the temperature of the reaction solution at temperature D, add Lewis acid. Control the temperature of the reaction solution to continue the reaction at temperature E. TLC detects the reaction until the raw material point disappears. After cooling, the reaction solution is slowly added to the ice-water mixture to quench the reaction, the organic phase is separated, and the aqueous phase is extracted with dichloromethane. Multiple times, the organic phases were combined, washed, dried, filtered, and the filtrate was evaporated under reduced pressure to remove the solvent, and then recrystallized with ethanol to obtain the key intermediate 1,2,6,7-tetra Hydrogen-8H-indeno[5,4-b]furan-8-one.
步骤3的方法二中所述的有机溶剂D可选择二氯甲烷、1,2-二氯乙烷、苯、甲苯、二甲苯、氯苯、二氯苯中的一种或多种混合溶剂。The organic solvent D described in method 2 of step 3 can be selected from one or more mixed solvents of dichloromethane, 1,2-dichloroethane, benzene, toluene, xylene, chlorobenzene, and dichlorobenzene.
步骤3的方法二中所述的Lewis酸可选择二氯化锡、四氯化锡、四氯化钛、三氯化铝、三氯化铁、高氯酸铁、高氯酸亚铁、三氟甲磺酸铁、三氟甲磺酸亚铁、高氯酸钴、三氟甲磺酸铜、高氯酸铜、三氟甲磺酸钪、三氟甲磺酸铟、醋酸钯(II)、双乙腈氯化钯(II)、三氟化硼乙醚络合物、三氟甲磺酸三甲基硅酯、沸石分子筛、改性的沸石分子筛中的一种。The Lewis acid described in the method two of step 3 can select tin dichloride, tin tetrachloride, titanium tetrachloride, aluminum trichloride, iron trichloride, ferric perchlorate, ferrous perchlorate, three Ferric fluoromethanesulfonate, ferrous trifluoromethanesulfonate, cobalt perchlorate, copper trifluoromethanesulfonate, copper perchlorate, scandium trifluoromethanesulfonate, indium trifluoromethanesulfonate, palladium(II) acetate , bisacetonitrile palladium(II) chloride, boron trifluoride etherate complex, trimethylsilyl trifluoromethanesulfonate, zeolite molecular sieve, and modified zeolite molecular sieve.
步骤3的方法二中所述的温度D的范围为-10~10℃,温度E的范围为20~120℃。The range of temperature D in method 2 of step 3 is -10-10°C, and the range of temperature E is 20-120°C.
步骤3的方法二中所述的式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮和Lewis酸的投料摩尔比为1:0.01~1.5。The molar ratio of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one and Lewis acid represented by formula IV described in method 2 of step 3 is 1:0.01 ~1.5.
本发明所提供的式I所示的雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮,可用于雷美替胺的合成制备。具体的合成路线和方法可参见以下文献:中国医药工业杂志,2009,40,161-164;中国专利CN20081004587.5;PCT专利WO2006030739。The ramelteon key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one represented by formula I provided by the present invention can be used for ramelteon Synthetic preparation of amines. The specific synthetic route and method can be found in the following documents: Chinese Journal of Pharmaceutical Industry, 2009, 40, 161-164; Chinese patent CN20081004587.5; PCT patent WO2006030739.
本发明所提供的式I所示的雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的合成制备方法,其创新性体现在以下几点:The synthesis and preparation method of ramelteon key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one shown in formula I provided by the present invention, which The innovation is reflected in the following points:
(1)采用2,3-二氢苯并呋喃-4-甲醛为起始原料经过三步反应制得式I所示的雷美替胺关键中间体,合成路线简洁,总收率高;(1) Using 2,3-dihydrobenzofuran-4-carbaldehyde as the starting material to prepare the key intermediate of ramelteon shown in formula I through three-step reaction, the synthetic route is simple and the total yield is high;
(2)反应的选择性高,无需占位,大大降低了副反应的发生,降低了最终产品的杂质个数和总杂质的含量,有利于提高产品质量;(2) The selectivity of the reaction is high, without occupying a place, which greatly reduces the occurrence of side reactions, reduces the number of impurities and the content of total impurities in the final product, and is conducive to improving product quality;
(3)路线中未使用溴素等产生大量酸性废水的试剂原料,更加绿色环保;(3) Bromine and other reagent raw materials that generate a large amount of acidic wastewater are not used in the route, which is more green and environmentally friendly;
(4)工艺操作简便,稳定性和可控性高,适合工业化大生产。(4) The process is easy to operate, has high stability and controllability, and is suitable for large-scale industrial production.
总之,本发明所提供的式I所示的合成雷美替胺的关键中间体的合成制备方法,具有反应选择性高、副反应少、总收率和产品质量高、对环境友好、工艺操作简便且稳定性和可控性高等优点,适合于工业化大生产。In a word, the synthesis and preparation method of the key intermediate of synthetic ramelteon shown in formula I provided by the present invention has high reaction selectivity, few side reactions, high overall yield and product quality, environmental friendliness, and process operation It has the advantages of simplicity, high stability and controllability, and is suitable for large-scale industrial production.
具体实施方式Detailed ways
以下典型实施例用来举例说明本发明,在本领域内的技术人员对本发明所做的简单替换或改进等均属于本发明所保护的技术方案之内。The following typical embodiments are used to illustrate the present invention. Simple replacements or improvements made by those skilled in the art are within the technical solutions protected by the present invention.
实施例1:1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇(Ⅲ)的合成制备Example 1: Synthesis and preparation of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ol (Ⅲ)
反应式如下:The reaction formula is as follows:
在反应瓶中加入1.0M的乙烯基溴化镁的四氢呋喃溶液1050mL(1.05mol),开启搅拌,将反应液冷却到-10~-5℃,滴加2,3-二氢苯并呋喃-4-甲醛(148.2g,1.00mol)的四氢呋喃(500mL)溶液,并控制反应液的温度不超过-5℃。滴加完毕后,保持温度在-10~-5℃反应半小时后,再缓慢升温至室温继续反应。6小时后,加入饱和氯化铵水溶液300mL,搅拌30分钟后,用乙酸乙酯萃取三次(800mL×3)。有机相用饱和氯化钠溶液(300mL)和水(300mL)各洗涤一次,无水硫酸钠干燥后,过滤,滤液减压浓缩至干得黄色油状物173.6g,收率98.5%。Add 1050mL (1.05mol) of 1.0M tetrahydrofuran solution of vinylmagnesium bromide into the reaction flask, start stirring, cool the reaction solution to -10~-5°C, add dropwise 2,3-dihydrobenzofuran-4 -formaldehyde (148.2g, 1.00mol) in tetrahydrofuran (500mL) solution, and control the temperature of the reaction solution not to exceed -5°C. After the dropwise addition, keep the temperature at -10~-5°C and react for half an hour, then slowly raise the temperature to room temperature to continue the reaction. After 6 hours, 300 mL of saturated aqueous ammonium chloride solution was added, stirred for 30 minutes, and extracted three times with ethyl acetate (800 mL×3). The organic phase was washed once each with saturated sodium chloride solution (300 mL) and water (300 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain 173.6 g of a yellow oil with a yield of 98.5%.
实施例2:1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮(IV)的合成制备Example 2: Synthesis and preparation of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one (IV)
反应式如下:The reaction formula is as follows:
室温下,在反应瓶中加入750mL的二甲亚砜溶剂,再加入式III所述的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇150.0g(0.85mol),搅拌溶解,室温下分批加入2-碘酰基苯甲酸(IBX)360g(1.29mol),约10分钟加料完毕。继续在室温反应2小时后,TLC检测,原料点消失。加入乙酸乙酯2.5L,搅拌15分钟后,过滤,滤液用水洗涤二次(850mL×2),无水硫酸钠干燥,过滤,滤液减压蒸除溶剂后,即得黄色油状物139.2g,收率94.1%。At room temperature, add 750 mL of dimethyl sulfoxide solvent into the reaction flask, and then add 150.0 g of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ol described in formula III (0.85mol), stirring and dissolving, adding 360g (1.29mol) of 2-iodobenzoic acid (IBX) in batches at room temperature, and the addition was completed in about 10 minutes. After continuing to react at room temperature for 2 hours, TLC detected that the raw material point disappeared. Add 2.5L of ethyl acetate, stir for 15 minutes, filter, wash the filtrate twice with water (850mL×2), dry over anhydrous sodium sulfate, filter, and distill the filtrate to remove the solvent under reduced pressure to obtain 139.2g of a yellow oil. The rate is 94.1%.
实施例3:1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮(IV)的合成制备Example 3: Synthesis and preparation of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one (IV)
反应式如下:The reaction formula is as follows:
在反应瓶中加入1500mL的二氯甲烷和式III所述的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇130.0g(0.74mol),搅拌溶解,室温下加入(1,1,1-三乙酰氧基)-1,1-二氢-1,2-苯碘酰-3(1H)-酮(DMP)410g(0.97mol)。继续在室温下反应2小时后,TLC检测,原料点消失。加入乙酸乙酯1000mL、10%的Na2S2O3溶液150mL和饱和NaHCO3溶液200mL,剧烈搅拌1小时后,分出有机相,用饱和食盐水(800mL)和水(800mL)各洗涤一次,无水硫酸钠干燥,过滤,滤液减压蒸除溶剂后,即得黄色油状物124.8g,收率97.3%。Add 1500 mL of dichloromethane and 130.0 g (0.74 mol) of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-ol described in formula III to the reaction flask, stir to dissolve 410 g (0.97 mol) of (1,1,1-triacetoxy)-1,1-dihydro-1,2-phenyliodide-3(1H)-one (DMP) was added at room temperature. After continuing to react at room temperature for 2 hours, TLC detected that the raw material point disappeared. Add 1000 mL of ethyl acetate, 150 mL of 10% Na 2 S 2 O 3 solution and 200 mL of saturated NaHCO 3 solution, stir vigorously for 1 hour, separate the organic phase, and wash with saturated brine (800 mL) and water (800 mL) once each , dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to remove the solvent under reduced pressure to obtain 124.8 g of a yellow oil with a yield of 97.3%.
实施例4:1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮(IV)的合成制备Example 4: Synthesis and preparation of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one (IV)
反应式如下:The reaction formula is as follows:
在反应瓶中加入无水二氯甲烷1000mL,开启搅拌,控制体系的温度不超过20℃下,向二氯甲烷溶剂中加入干燥的三氧化铬492.0g(4.92mol)和无水吡啶778.3g(9.84mol),继续在室温下搅拌1小时后,一次性加入式III所述的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-醇(144.5g,0.82mol)的二氯甲烷(400mL)溶液,并继续在室温下反应1小时,TLC检测,原料点消失。反应液过滤后,滤液用饱和食盐水(300mL)和水(400mL)各洗涤一次,无水硫酸钠干燥,过滤,滤液减压蒸除溶剂后,即得黄色油状物121.7g,收率85.4%。Add 1000 mL of anhydrous dichloromethane into the reaction flask, start stirring, and control the temperature of the system not to exceed 20°C, add 492.0 g (4.92 mol) of dry chromium trioxide and 778.3 g of anhydrous pyridine ( 9.84mol), after continuing to stir at room temperature for 1 hour, 1-(2,3-dihydrobenzofuran-4-yl)-2-propene-1-alcohol (144.5g, 0.82mol) in dichloromethane (400mL) solution, and continue to react at room temperature for 1 hour, TLC detection, the raw material point disappeared. After the reaction solution was filtered, the filtrate was washed once with saturated brine (300mL) and water (400mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to remove the solvent under reduced pressure to obtain 121.7g of a yellow oil with a yield of 85.4% .
实施例5:雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮(I)的合成制备Example 5: Synthesis and preparation of ramelteon key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one (I)
反应式如下:The reaction formula is as follows:
室温下,向反应瓶中加入三氟甲磺酸300ml和式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮94.0g(0.54mol),继续在室温下反应17小时后,TLC检测,原料点消失。将反应液倒入300g的冰水混合物中,搅拌30分钟后,用二氯甲烷萃取三次(400ml×3)。有机相再用饱和食盐水(300mL)和水(300mL)各洗涤一次,无水硫酸钠干燥,过滤,滤液减压蒸除溶剂后,残余物用乙醇重结晶,得类白色固体67.6g,收率71.9%。At room temperature, add 300ml of trifluoromethanesulfonic acid and 94.0g (0.54mol ), after continuing to react at room temperature for 17 hours, TLC detected that the raw material point disappeared. The reaction solution was poured into 300 g of ice-water mixture, stirred for 30 minutes, and extracted three times with dichloromethane (400 ml×3). The organic phase was washed once each with saturated brine (300 mL) and water (300 mL), dried over anhydrous sodium sulfate, and filtered. After the filtrate was evaporated to remove the solvent under reduced pressure, the residue was recrystallized with ethanol to obtain 67.6 g of an off-white solid. The rate is 71.9%.
实施例6:雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮(I)的合成制备Example 6: Synthesis and preparation of ramelteon key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one (I)
反应式如下:The reaction formula is as follows:
在反应瓶中加入二氯甲烷450ml和式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮98.5g(0.56mol),搅拌溶解后,控制体系的温度不超过10℃下缓慢加入无水三氯化铁100g(0.62mol),随后升温至室温下反应8小时后,TLC检测,原料点消失。将反应液倒入260g的冰水混合物中,搅拌半小时后,分出有机相,再用二氯甲烷萃取水相二次(150ml×2),合并有机相后用饱和食盐水(200mL)和水(200mL)各洗涤一次,无水硫酸钠干燥,过滤,滤液减压蒸除溶剂后,残余物用乙醇重结晶,得类白色固体91.6g,收率93.0%。Add 450ml of dichloromethane and 98.5g (0.56mol) of 1-(2,3-dihydrobenzofuran-4-yl)-2-propen-1-one shown in formula IV into the reaction flask, stir and dissolve 100 g (0.62 mol) of anhydrous ferric chloride was slowly added under the control system temperature not exceeding 10° C., and then the temperature was raised to room temperature and reacted for 8 hours. TLC detected that the raw material point disappeared. The reaction solution was poured into 260g of ice-water mixture, after stirring for half an hour, the organic phase was separated, and the aqueous phase was extracted twice with dichloromethane (150ml×2). Water (200 mL) was washed once each, dried over anhydrous sodium sulfate, filtered, the filtrate was evaporated to remove the solvent under reduced pressure, and the residue was recrystallized with ethanol to obtain 91.6 g of off-white solid, yield 93.0%.
实施例7:雷美替胺关键中间体1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮(I)的合成制备Example 7: Synthesis and preparation of ramelteon key intermediate 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one (I)
反应式如下:The reaction formula is as follows:
在反应瓶中加入1,2-二氯乙烷450ml和式IV所示的1-(2,3-二氢苯并呋喃-4-基)-2-丙烯-1-酮92.3g(0.53mol),搅拌溶解后,控制体系的温度不超过10℃下缓慢加入三氟甲磺酸铜19.2g(0.053mol),随后升温至室温下反应16小时后,TLC检测,原料点消失。将反应液倒入200g的冰水混合物中,搅拌半小时后,分出有机相,再用1,2-二氯乙烷萃取水相二次(150ml×2),合并有机相后用饱和食盐水(200mL)和水(200mL)各洗涤一次,无水硫酸钠干燥,过滤,滤液减压蒸除溶剂后,残余物用乙醇重结晶,得类白色固体88.9g,收率96.3%。Add 450ml of 1,2-dichloroethane and 92.3g (0.53mol ), after stirring and dissolving, 19.2 g (0.053 mol) of copper trifluoromethanesulfonate was slowly added under control of the temperature of the system not exceeding 10° C., and then heated to room temperature and reacted for 16 hours. TLC detected that the raw material point disappeared. Pour the reaction solution into 200g of ice-water mixture, stir for half an hour, separate the organic phase, then extract the water phase with 1,2-dichloroethane twice (150ml×2), combine the organic phases and wash with saturated salt Water (200 mL) and water (200 mL) were washed once each, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to remove the solvent under reduced pressure, and the residue was recrystallized with ethanol to obtain 88.9 g of off-white solid with a yield of 96.3%.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510237694.5A CN104926763B (en) | 2015-05-11 | 2015-05-11 | A kind of synthetic preparation method of ramelteon key intermediate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510237694.5A CN104926763B (en) | 2015-05-11 | 2015-05-11 | A kind of synthetic preparation method of ramelteon key intermediate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104926763A true CN104926763A (en) | 2015-09-23 |
CN104926763B CN104926763B (en) | 2019-09-20 |
Family
ID=54114218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510237694.5A Active CN104926763B (en) | 2015-05-11 | 2015-05-11 | A kind of synthetic preparation method of ramelteon key intermediate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104926763B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109160909A (en) * | 2018-10-30 | 2019-01-08 | 雅本化学股份有限公司 | A kind of thunder rice replaces the preparation method of amine |
CN113045524A (en) * | 2021-03-24 | 2021-06-29 | 河南牧业经济学院 | Synthesis method of ramelteon intermediate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101671323A (en) * | 2008-09-10 | 2010-03-17 | 上海朴颐化学科技有限公司 | Method for synthesizing 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ketone |
-
2015
- 2015-05-11 CN CN201510237694.5A patent/CN104926763B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101671323A (en) * | 2008-09-10 | 2010-03-17 | 上海朴颐化学科技有限公司 | Method for synthesizing 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ketone |
Non-Patent Citations (1)
Title |
---|
蒋龙等: "雷美替胺的合成", 《中国医药工业杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109160909A (en) * | 2018-10-30 | 2019-01-08 | 雅本化学股份有限公司 | A kind of thunder rice replaces the preparation method of amine |
CN113045524A (en) * | 2021-03-24 | 2021-06-29 | 河南牧业经济学院 | Synthesis method of ramelteon intermediate |
CN113045524B (en) * | 2021-03-24 | 2023-09-22 | 河南牧业经济学院 | Synthesis method of ramelteon intermediate |
Also Published As
Publication number | Publication date |
---|---|
CN104926763B (en) | 2019-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102653533B (en) | Total synthesis method of mangostin | |
CN112679420B (en) | Preparation method of 2,5-dibromopyridine | |
Park et al. | Facile synthesis of regio-isomeric naphthofurans and benzodifurans | |
Li et al. | Synthetic strategies in the construction of chromones. | |
CN103113293B (en) | Polysubstituted quinoline derivative and preparation method thereof | |
CN104926763B (en) | A kind of synthetic preparation method of ramelteon key intermediate | |
CN106316946B (en) | A kind of α of Ciprofloxacin, alpha, beta-unsaturated ketone derivative and its preparation method and application | |
CN106317014B (en) | A kind of α of Lomefloxacin, alpha, beta-unsaturated ketone derivative and its preparation method and application | |
CN105218499A (en) | A kind of method preparing Scutellarein | |
CN101633647B (en) | Method for synthesizing alpha-azyl aryl alkyl ketone compound with high selectivity and high yield | |
CN112824391B (en) | A kind of propenone derivative of gatifloxacin and its preparation method and application | |
Al-Zoubi et al. | Domino C–C/C–O bond formation: palladium-catalyzed regioselective synthesis of 7-iodobenzo [b] furans using 1, 2, 3-triiodobenzenes and benzylketones | |
CN106831397A (en) | A kind of anthraquinone analog compound and preparation method thereof and medical application | |
Yamato et al. | Synthesis and antitumor activity of tropolone derivatives. 3 | |
CN104003968A (en) | Natural product 3-prenyl Iuteolin analogue (I)/(II), preparation method of natural product 3-prenyl Iuteolin analogue (I)/(II), and application of natural product 3-prenyl Iuteolin analogue (I)/(II) | |
CN112824397B (en) | Lomefloxacin propenone derivative and preparation method and application thereof | |
CN103864747B (en) | The total synthesis method of mangostin | |
JP2019509293A (en) | 4-Pentafluorothiophenol compounds and preparation method, and preparation method of pentafluorosulfur-substituted benzopyran compounds | |
JP2023549213A (en) | How to prepare cannabis flavonoids | |
CN111320578A (en) | A kind of acrylone derivative of de-N-methyl fleroxacin and its preparation method and application | |
CN112824388B (en) | Acrylic ketone derivative of norfloxacin and preparation method and application thereof | |
CN110105316B (en) | A kind of resveratrol-phthalide hybrid compound and its preparation method and use | |
CN103936701B (en) | A kind of preparation method of Aurone compound | |
CN107501061A (en) | A kind of preparation method of the ketone of 2 methoxyl group, 6,7,8,9 tetrahydro benzo cycloheptane 5 | |
CN112574170A (en) | Dibenzo seven-membered ring derivative and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170921 Address after: 213200, No. 6, Chang Dong Road, Jintan, Jiangsu, Changzhou Applicant after: Changzhou Yabang Pharmaceutical Co., Ltd. Address before: 213200, No. 6, Chang Dong Road, Jintan, Jiangsu, Changzhou Applicant before: Changzhou Yabang Pharmaceutical Co., Ltd. Applicant before: Changzhou Yabang Pharmaceutical & Chemical Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |